Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group

Journal of Clinical Oncology

Volumn 21, Issue 18, 2003, Pages 3440-3446

  Josting, Andreas ^a   Wiedenmann, Sabine ^a   Franklin, Jeremy ^a   May, Michael ^a   Sieber, Markus ^a   Wolf, Juergen ^a   Engert, Andreas ^a   Diehl, Volker ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; PREDNISONE; PROCARBAZINE; TIOGUANINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG MEGADOSE; HODGKIN DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; ACUTE DISEASE; FEMALE; MALE; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; RETROSPECTIVE STUDY; SECOND CANCER; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 0142058040     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.160     Document Type: Article

References (28)

1. Rosenberg SA: The management of Hodgkin's disease: Half a century of change. Ann Oncol 7:555-562, 1996
2. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's Disease. Ann Oncol 3:S117-S128, 1992 (suppl 4)
3. Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81, 1988
4. Van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al: Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12:1063-1073, 1994
5. Rueffer U, Josting A, Franklin J, et al: Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: Incidence, treatment, and prognosis. J Clin Oncol 19:2026-2032, 2001
6. Ng AK, Bernardo MV, Weller E, et al: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100:1989-1996, 2002
7. Anderson JE, Gooley TA, Schoch G, et al: Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 89:25782585, 1997
8. Dann EJ, Rowe JM: Biology and therapy of secondary leukaemias. Best Pract Res Clin Haematol 1:119-137, 2001
9. Witherspoon RP, Deeg HJ, Storer B, et al: Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 19:2134-2141, 2001
10. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Diehl V, Franklin J, Paulus U, et al: BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood 98:769, 2001 (abstr 3202a, suppl 1)
12. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
13. Valagussa P: Second neoplasms following treatment of Hodgkin's disease. Curr Opin Oncol 5:805-811, 1993
14. Horning SJ, Williams J, Bartlett NL, et al: Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 18:972-980, 2000
15. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12:312-325, 1994
16. Munker R, Grutzner S, Hiller E, et al: Second malignancies after Hodgkin's disease: The Munich experience. Ann Hematol 78:544-554, 1999
17. Andre M, Henry-Amar M, Blaise D, et al: Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 92:1933-1940, 1998
18. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al: Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. EBMT Lymphoma and Late Effects Working Parties European Group for Blood and Marrow Transplantation. Br J Haematol 106:1020-1026, 1999
19. Ratain M, Rowley J: Therapy related acute myeloid leukemia secondary to inhibitors of topoisomerase II: From the bedside to target genes. Ann Oncol 3:107-111, 1992
20. Greaver M: Aetiology of acute leukemia. Lancet 349:344-349, 1997
21. Micallef IN, Lillington DM, Apostolidis J, et al: Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947-955, 2000
22. Neugut AI, Robinson E, Nieves J, et al: Poor survival of treatment-related acute nonlymphocytic leukemia. J Am Med Assoc 264:1006-1008, 1990
23. Friedberg JW, Neuberg D, Stone RM, et al: Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. J Clin Oncol 17:3128-3135, 1999
24. Harrison CN, Vaughan G, Devereux S, et al: Outcome of secondary myeloid malignancy in Hodgkin's disease: The BNLI experience. Eur J Haematol 61:109-112, 1998
25. de Witte T, Suciu S, Verhoef G, et al: Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98:2326-2331, 2001
26. Schoch C, Haferlach T, Schnittger S, et al: Prognostic significance of chromosome aberrations in therapy-associated acute myeloid leukemia. Blood 94:911, 1999 (abstr 2033a, suppl 2)
27. Khouri IF, Keating M, Korbling M, et al: Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817-2824, 1998
28. Kottaridis PD, Chakraverty R, Milligan DW, et al: A non-myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GvHD, disease control, and potential for GvL with adoptive immunotherapy. Blood 94:266, 1999 (abstr 348a, suppl 1)